Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.

× No keyword cloud information.

12 in total

1. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.

Authors: Sudhanshu Shukla; Joseph R Evans; Rohit Malik; Felix Y Feng; Saravana M Dhanasekaran; Xuhong Cao; Guoan Chen; David G Beer; Hui Jiang; Arul M Chinnaiyan
Journal: J Natl Cancer Inst Date: 2016-10-05 Impact factor: 13.506

2. The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.

Authors: Shane Dormady; Michael S Broder; Girish V Putcha; Robert H Dumanois; Alison H DeCristofaro; Eunice Chang; Paul R Billings; Thierry Jahan
Journal: Int J Clin Oncol Date: 2014-06-06 Impact factor: 3.402

Review 3. Prognostic markers in lung cancer: is it ready for prime time?

Authors: Chang-Qi Zhu; Ming-Sound Tsao
Journal: Transl Lung Cancer Res Date: 2014-06

Review 4. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.

Authors: Johannes R Kratz; Michael J Mann; David M Jablons
Journal: Transl Lung Cancer Res Date: 2013-06

5. Is there clinical value to prognostic signatures in early-stage NSCLC?

Authors: Paul A Bunn; Fred R Hirsch; Dara L Aisner
Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531

6. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Authors: Ignacio I Wistuba; Carmen Behrens; Francesca Lombardi; Susanne Wagner; Junya Fujimoto; M Gabriela Raso; Lorenzo Spaggiari; Domenico Galetta; Robyn Riley; Elisha Hughes; Julia Reid; Zaina Sangale; Steven G Swisher; Neda Kalhor; Cesar A Moran; Alexander Gutin; Jerry S Lanchbury; Massimo Barberis; Edward S Kim
Journal: Clin Cancer Res Date: 2013-09-18 Impact factor: 12.531

A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.

1. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.

2. The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.

Review 3. Prognostic markers in lung cancer: is it ready for prime time?

Review 4. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.

5. Is there clinical value to prognostic signatures in early-stage NSCLC?

6. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Review 7. Prognostic and predictive biomarkers post curative intent therapy.

8. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

9. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.

Review 10. [Comprehensive Treatment for Lung Cancer  Based on Minimally Invasive Thoracic Surgery].

A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.

1. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.

2. The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer.

Review 3. Prognostic markers in lung cancer: is it ready for prime time?

Review 4. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.

5. Is there clinical value to prognostic signatures in early-stage NSCLC?

6. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Review 7. Prognostic and predictive biomarkers post curative intent therapy.

8. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

9. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.

Review 10. [Comprehensive Treatment for Lung Cancer Based on Minimally Invasive Thoracic Surgery].

Review 10. [Comprehensive Treatment for Lung Cancer  Based on Minimally Invasive Thoracic Surgery].